ESMO-Magnitude of Clinical Benefit Scale

MCBS Banner 1180x184

The ESMO-MCBS is a standardised, generic, validated tool to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies at the time of approval.

The below filter has been created to provide a centralised location of cancer medicines that have been scored using ESMO-MCBS v1.1 and published by ESMO.

ESMO-MCBS grading

Curative setting grading  - A (major benefit), B (important benefit), C (minor benefit):

  • Form 1   - For new approaches to adjuvant therapy or new potentially curative therapies

Non-curative setting grading - 5 and 4 (substantial benefit), 3 (moderate benefit), 2 and 1 (negligible benefit):

  • Form 2a   - For therapies that are not likely to be curative with primary endpoint of OS 
  • Form 2b   - For therapies that are not likely to be curative with primary endpoint PFS 
  • Form 2c   - For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies 
  • Form 3     - For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR 

For full information please click here

The ESMO-MCBS Score Card

The ESMO-MCBS Score Card allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Tested Agent Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Tumour Stage Score Ref. Score card
FOLFIRINOX Gemcitabine 1st line advanced or metastatic. Good performance status Gastrointestinal Cancers Pancreatic cancer Metastatic
5
Nivolumab Chemotherapy Platinum-refractory metastatic H+N squamous cell cancer stratified for PD-L1 Head and neck cancer Squamous cell Metastatic
5
Pembrolizumab Docetaxel 2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC>1% tumour cell PD-L1 expression (all) Pembro 10mg/kg Thoracic Malignancies Non-small-cell Lung Cancer Metastatic
5
Pembrolizumab Docetaxel 2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC >50% tumour cell PD-L1 expression Pembro 2mg/kg Thoracic Malignancies Non-small-cell Lung Cancer Metastatic
5
Pembrolizumab Docetaxel 2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC>50% tumour cell PD-L1 expression Pembro 10mg/kg Thoracic Malignancies Non-small-cell Lung Cancer Metastatic
5
Nivolumab Docetaxel 2nd line after platinum-based therapy advanced squamous-cell NSCLC Thoracic Malignancies Non-small-cell Lung Cancer Squamous cell Metastatic
5
Nivolumab Docetaxel 2nd line after platinum-based therapy advanced non-squamous-cell NSCLC stratified for PD-L1 Thoracic Malignancies Non-small-cell Lung Cancer Non-squamous cell Metastatic
5
Radium-223 Best standard of care Best standard of care + placebo Late line and bone pain, castration-refractory, late line and bone pain Genitourinary Cancers Prostate cancer Metastatic
5
Nivolumab Everolimus 2nd line RCC clear cell after TKI Genitourinary Cancers Renal cell cancer Metastatic
5
Atezolizumab Docetaxel Squamous or non-squamous stage IIIB or IV patients who had previously received one or two chemotherapy regimes Thoracic Malignancies Squamous or non-squamous non-small-cell lung cancer Metastatic
5

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings